The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.

about

Developments in HIV-1 immunotherapy and therapeutic vaccination.CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

P2860

Q30364312-8C9ED4E7-9568-41C6-AB5D-39A93EF71A2C Q38803127-24A581AE-1BE6-405B-B856-0993DF368555

P2860

The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.

Item

http://www.wikidata.org/entity/Q38056759

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The MOTIVATE trials: maraviroc ...... enced HIV-1-infected patients.

@en

type

Item

label

The MOTIVATE trials: maraviroc ...... enced HIV-1-infected patients.

@en

prefLabel

The MOTIVATE trials: maraviroc ...... enced HIV-1-infected patients.

@en

P1476

The MOTIVATE trials: maraviroc ...... enced HIV-1-infected patients.

@en

P2093

Andy I M Hoepelman

http://www.w3.org/2001/XMLSchema#string

Annemarie M J Wensing

http://www.w3.org/2001/XMLSchema#string

Steven F L van Lelyveld

http://www.w3.org/2001/XMLSchema#string

P2860

Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals

Identification of a major co-receptor for primary isolates of HIV-1

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

HIV infection, inflammation, immunosenescence, and aging.

P304

1241-1247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERI.12.114

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23113664

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.

about

P2860

P2860

The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921